Laser Ablation of Papillary Thyroid Microcarcinoma
United States10 participantsStarted 2020-10-19
Plain-language summary
The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* Papillary thyroid cancer documented by
* (a) Bethesda VI cytology,
* (b) Bethesda III, IV, V, or VI cytology AND BRAF V600E mutation, or
* (c) Bethesda V cytology AND high risk ultrasonographic features documented by either the ATA high suspicion or TIRADS 5 nodule characteristics
To ensure the majority of cases will be eligible based on criteria (a) or (b), we will enroll ≤ 2 patients based on criteria (c).
* Maximum diameter ≤ 13 mm
* Declined active surveillance
* The thyroid lesion must be primarily solid with ≤ 25% cystic compent
* No US evidence of extrathyroidal extension through the thyroid capsule
* No imaging evidence of lymph node metastasis
* Preserved contralateral vocal cord function prior to PLA
Exclusion Criteria:
* Thyroid cancer that is non papillary thyroid cancer (PTC)
* Thyroid lesion with \> 25% cystic component
* Lesion with US evidence of extrathyroidal extension through the thyroid capsule
* Clinical or ultrasonographic evidence of lymph node metastasis
* Pregnancy
What they're measuring
1
Number of participants with complete thermal ablation